The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Advisory Board Appointment

18 Aug 2021 07:00

RNS Number : 9416I
DeepMatter Group PLC
18 August 2021
 

18 August 2021

 

DeepMatter Group Plc

DeepMatter CEO appointed Chairman of Industrial Advisory Board at Imperial College

DeepMatter Group Plc (AIM: DMTR, "DeepMatter", the "Group"), which focuses on digitalising chemistry, announces that its CEO, Mark Warne, has been invited to chair the Industrial Advisory Board (IAB) at Imperial College's EPSRC Centre for Doctoral Training in Next Generation Synthesis & Reaction Technology (CDT), for the next two years.

Mark's principal role will be to liaise closely with the CDT's network of industrial partners, including AstraZeneca, Bayer, BASF, GlaxoSmithKline, IBM, The Janssen Pharmaceutical Companies of Johnson & Johnson, Mettler-Toledo, Syngenta, and Pfizer. 

These partners provide industrial advice and feedback on the CDT's research direction as well as making recommendations in the areas of chemistry, chemical engineering and data science.

Mark Warne, DeepMatter CEO, commented:

"This appointment will enable me to work closely with a number of multinational pharma companies and Key Opinion Leaders - all of whom are committed to integrating chemistry with technology and sharing their expertise and experience with the chemists of the future.

"This appointment is a further validation of DeepMatter's position at the centre of the digitalisation of chemistry and the development of big data and analytics for the chemists in early-stage formulation."

The CDT is made up of a multi-disciplinary team of internationally-leading researchers at Imperial College. It benefits from significant infrastructural and capital investment on its state-of-the-art technology and facilities such as The Centre for Rapid Online Analysis of Reactions (ROAR).

The CDT aims to engage with the Centres of Excellence in the US and Europe, to deliver a unique multi-faceted training programme in order to improve the skills, employability and productivity of the graduates and to equip them for future academic and industrial roles.

Jinata Subba, EPSRC CDT Programme Manager, Dept of Chemistry, Imperial College, added:

 "DeepMatter's knowledge and experience of automation in chemistry will help us on our mission to transform synthetic chemistry into a truly data-driven discipline. Automation enables researchers to gather and share huge amounts of data about chemical reactions, which can then be used to optimize processes and even forecast the outcomes of entirely new reactions.

"There is a skills gap between academic training and the experimental methods used routinely in industry. At Imperial College our programme aims to equip students for the future of synthetic chemistry. The advice and feedback from the Industrial Advisory Board is proving invaluable.

"DeepMatter's mission of digitising chemistry using cutting edge analytical instruments and Machine Learning techniques resonates with the way we are pioneering this approach to training."

 

For more information, please contact:

 

DeepMatter Group PlcMark Warne, Chief Executive Officer 0141 548 8156

Canaccord Genuity Limited (Nominated Advisor and Broker) 020 7523 8000Bobbie Hilliam

Meare Consulting 07990 858548Adrian Duffield

 

About DeepMatter Group Plc 

DeepMatter is building and commercialising the most powerful data platforms, to enable scientists to easily perform and optimise chemical reactions, by increasingly integrating chemistry with technology. Ultimately this will allow the greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics.

Visit: www.deepmatter.io and follow @deepmattergroup

 

About the EPSRC Centre for Doctoral Training in Next Generation Synthesis & Reaction Technology

The mission of the Next Generation Synthesis & Reaction Technology CDT is to educate a critical mass of researchers equipped to respond to future research challenges and opportunities created by the data-revolution. The aim is to train highly qualified researchers with the ability to collect data using automated, high-throughput reaction platforms, and to apply quantitative and statistical approaches to data analysis and utilisation. This will be achieved by incorporating cross-disciplinary skills from engineering, as well as computing, statistics, and informatics into a chemistry graduate programme, which are largely lacking from existing doctoral training in synthetic chemistry.

Visit: www.imperial.ac.uk/next-generation-synthesis-reaction-technology/the-cdt-programme/

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABUGDIBGBDGBR
Date   Source Headline
24th Jan 20228:50 amRNSHolding(s) in Company
24th Jan 20227:00 amRNSHolding(s) in Company
20th Jan 202212:15 pmRNSResult of General Meeting
20th Jan 20227:00 amRNSResult of Open Offer - Correction
19th Jan 202211:30 amRNSResult of Open Offer
4th Jan 20221:30 pmRNSPosting of Circular and Notice of GM
29th Dec 20214:36 pmRNSPrice Monitoring Extension
24th Dec 20217:00 amRNSPlacing, Subscription and Open Offer
17th Dec 20215:00 pmRNSBusiness Update and Financing
22nd Oct 20217:00 amRNSAppointment of new Scientific Advisory Board
21st Oct 20218:00 amRNSDigitalGlassware® platform trial with Aurigene
28th Sep 20217:00 amRNSCollaboration
22nd Sep 20217:00 amRNSHalf Year Results
14th Sep 202110:30 amRNSNotice of Half Year Results
8th Sep 20211:30 pmRNSHolding(s) in Company
18th Aug 20217:00 amRNSAdvisory Board Appointment
5th Aug 20217:00 amRNSCollaboration with the University of Cambridge
12th Jul 20217:00 amRNSAppointment of Non-Executive Director
30th Jun 20213:34 pmRNSResult of AGM
22nd Jun 20217:00 amRNSChanges to 2021 AGM Arrangements
17th Jun 20217:00 amRNSCollaboration with the University of Leeds
8th Jun 20213:16 pmRNSPosting of ARA and Updated Notice of AGM
1st Jun 20217:00 amRNSFinal Results
24th May 20217:00 amRNSNotice of Results and Investor Presentation
6th May 20213:43 pmRNSHolding(s) in Company
7th Apr 20217:00 amRNSCollaboration with the University of Nottingham
11th Mar 20217:00 amRNSCo-distribution agreement with Elemental Machines
9th Mar 20217:00 amRNSDirectorate Change
20th Jan 20217:00 amRNSAgreement with Merck's Life Sciences business
19th Jan 20217:00 amRNSHolding(s) in Company
8th Jan 20212:00 pmRNSPrice Monitoring Extension
18th Dec 202010:30 amRNSGrant of PDMR Options
17th Dec 20207:00 amRNSMulti-year contract with Thieme Chemistry
26th Oct 202011:05 amRNSSecond Price Monitoring Extn
26th Oct 202011:00 amRNSPrice Monitoring Extension
21st Oct 20207:00 amRNSIssue of Shares and Total Voting Rights
19th Oct 20207:00 amRNSDirectorate Changes
16th Oct 20207:00 amRNSStrong adoption of ICSYNTH
2nd Oct 20202:05 pmRNSSecond Price Monitoring Extn
2nd Oct 20202:00 pmRNSPrice Monitoring Extension
1st Oct 20208:00 amRNSGrant of Options
29th Sep 20207:00 amRNSHolding(s) in Company
23rd Sep 20201:40 pmRNSHolding(s) in Company
22nd Sep 20204:29 pmRNSHolding(s) in Company
22nd Sep 20204:00 pmRNSHolding(s) in Company
22nd Sep 202010:32 amRNSHolding(s) in Company
15th Sep 20208:08 amRNSIssue of Shares and Total Voting Rights
10th Sep 20207:00 amRNSHalf-year Report
4th Sep 20208:26 amRNSHolding(s) in Company
3rd Sep 20207:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.